A Novel Cosmetic Formulation That Rapidly Reduces Hair Shedding in Females

In this prospective, placebo-controlled study, the researchers observed a significant reduction in hair shedding in women after applying the combined topical treatment DA-OTC-002, containing synephrine and TAAR agonists, compared to placebo, showing a 62.5% average reduction with no reported adverse events.

This study reports that a new topical solution, AB-102, containing a high concentration of a weak α1 agonist, significantly reduces hair shedding during brushing by up to 77% without causing cardiac or hemodynamic adverse events.

This study found that a shampoo with a selective TAAR agonist reduced hair shedding during brushing by 31% in women and contracted the arrector pili muscle.

This study found that a novel drinkable supplement significantly increased hair density and reduced hair shedding over six months in women with telogen effluvium, although the authors emphasize the need for larger, placebo-controlled trials to confirm these promising results.

This study found that topical phenylephrine, an α1-AR agonist, significantly reduced hair shedding and increased epilation force threshold in women experiencing traction alopecia during cosmetic procedures.